000136371 001__ 136371
000136371 005__ 20240321220045.0
000136371 0247_ $$2doi$$a10.1016/j.ejca.2011.06.026
000136371 0247_ $$2pmid$$apmid:21745734
000136371 0247_ $$2ISSN$$a0014-2964
000136371 0247_ $$2ISSN$$a0959-8049
000136371 0247_ $$2ISSN$$a1879-0852
000136371 0247_ $$2ISSN$$a1879-2995
000136371 037__ $$aDZNE-2020-02693
000136371 041__ $$aEnglish
000136371 082__ $$a610
000136371 1001_ $$0P:(DE-HGF)0$$aKoppelmans, Vincent$$b0
000136371 245__ $$aIncidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy.
000136371 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2011
000136371 264_1 $$2Crossref$$3print$$bElsevier BV$$c2011-11-01
000136371 3367_ $$2DRIVER$$aarticle
000136371 3367_ $$2DataCite$$aOutput Types/Journal article
000136371 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710772864_18974
000136371 3367_ $$2BibTeX$$aARTICLE
000136371 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136371 3367_ $$00$$2EndNote$$aJournal Article
000136371 520__ $$aIncidental brain findings defined as previously undetected abnormalities of potential clinical relevance that are unexpectedly discovered at brain imaging and are unrelated to the purpose of the examination are common in the general population. Because it is unclear whether the prevalence of incidental findings in breast cancer patients treated with chemotherapy is different to that in the general population, we compared the prevalence in breast cancer survivors treated with chemotherapy to that in a population-based sample of women without a history of any cancer.Structural brain MRI (1.5T) was performed in 191 female CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) chemotherapy-exposed breast cancer survivors. A reference group of 1590 women without a history of cancer was sampled from a population-based cohort study. All participants were aged 50 to 80 years. Five trained reviewers recorded the brain abnormalities. Two experienced neuro-radiologists reviewed the incidental findings.The cancer survivors had completed chemotherapy on average 21 years before. Of the 191 subjects, 2.6% had an aneurysm and 3.7% had a meningioma. The prevalence of meningiomas and aneurysms was not different between the groups. The prevalence of pituitary macro adenomas in the breast cancer survivors (1.6%) was higher than that in the reference group (0.1%) (OR=23.7; 95% CI 2.3-245.8).Contrary to commonly held opinions, we did not observe an increased prevalence of meningiomas in cancer survivors. Breast cancer survivors previously treated with chemotherapy are more likely to develop pituitary adenomas than persons without a history of cancer and chemotherapy treatment.
000136371 536__ $$0G:(DE-HGF)POF3-345$$a345 - Population Studies and Genetics (POF3-345)$$cPOF3-345$$fPOF III$$x0
000136371 542__ $$2Crossref$$i2011-11-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000136371 588__ $$aDataset connected to CrossRef, PubMed,
000136371 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000136371 650_7 $$08N3DW7272P$$2NLM Chemicals$$aCyclophosphamide
000136371 650_7 $$0U3P01618RT$$2NLM Chemicals$$aFluorouracil
000136371 650_7 $$0YL5FZ2Y5U1$$2NLM Chemicals$$aMethotrexate
000136371 650_2 $$2MeSH$$aAged
000136371 650_2 $$2MeSH$$aAged, 80 and over
000136371 650_2 $$2MeSH$$aAntineoplastic Agents: therapeutic use
000136371 650_2 $$2MeSH$$aAntineoplastic Combined Chemotherapy Protocols: administration & dosage
000136371 650_2 $$2MeSH$$aBreast Neoplasms: complications
000136371 650_2 $$2MeSH$$aBreast Neoplasms: drug therapy
000136371 650_2 $$2MeSH$$aChemotherapy, Adjuvant
000136371 650_2 $$2MeSH$$aCyclophosphamide: administration & dosage
000136371 650_2 $$2MeSH$$aFemale
000136371 650_2 $$2MeSH$$aFluorouracil: administration & dosage
000136371 650_2 $$2MeSH$$aHumans
000136371 650_2 $$2MeSH$$aIncidence
000136371 650_2 $$2MeSH$$aIncidental Findings
000136371 650_2 $$2MeSH$$aIntracranial Aneurysm: diagnosis
000136371 650_2 $$2MeSH$$aIntracranial Aneurysm: epidemiology
000136371 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000136371 650_2 $$2MeSH$$aMeningioma: diagnosis
000136371 650_2 $$2MeSH$$aMeningioma: epidemiology
000136371 650_2 $$2MeSH$$aMethotrexate: administration & dosage
000136371 650_2 $$2MeSH$$aMiddle Aged
000136371 650_2 $$2MeSH$$aNeoplasms, Second Primary: diagnosis
000136371 650_2 $$2MeSH$$aNeoplasms, Second Primary: epidemiology
000136371 650_2 $$2MeSH$$aPituitary Neoplasms: diagnosis
000136371 650_2 $$2MeSH$$aPituitary Neoplasms: epidemiology
000136371 650_2 $$2MeSH$$aSurvivors
000136371 7001_ $$0P:(DE-HGF)0$$aSchagen, Sanne B$$b1$$eCorresponding author
000136371 7001_ $$0P:(DE-HGF)0$$aPoels, Mariëlle M F$$b2
000136371 7001_ $$0P:(DE-HGF)0$$aBoogerd, Willem$$b3
000136371 7001_ $$0P:(DE-HGF)0$$aSeynaeve, Caroline$$b4
000136371 7001_ $$0P:(DE-HGF)0$$avan der Lugt, Aad$$b5
000136371 7001_ $$0P:(DE-2719)2810403$$aBreteler, Monique M B$$b6$$eLast author
000136371 77318 $$2Crossref$$3journal-article$$a10.1016/j.ejca.2011.06.026$$b : Elsevier BV, 2011-11-01$$n17$$p2531-2536$$tEuropean Journal of Cancer$$v47$$x0959-8049$$y2011
000136371 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2011.06.026$$gVol. 47, no. 17, p. 2531 - 2536$$n17$$p2531-2536$$q47:17<2531 - 2536$$tEuropean journal of cancer$$v47$$x0959-8049$$y2011
000136371 8564_ $$uhttps://pub.dzne.de/record/136371/files/DZNE-2020-02693_Restricted.pdf
000136371 8564_ $$uhttps://pub.dzne.de/record/136371/files/DZNE-2020-02693_Restricted.pdf?subformat=pdfa$$xpdfa
000136371 909CO $$ooai:pub.dzne.de:136371$$pVDB
000136371 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810403$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000136371 9131_ $$0G:(DE-HGF)POF3-345$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vPopulation Studies and Genetics$$x0
000136371 9141_ $$y2011
000136371 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136371 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136371 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136371 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136371 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2017
000136371 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136371 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136371 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000136371 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136371 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136371 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136371 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136371 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136371 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136371 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J CANCER : 2017
000136371 9201_ $$0I:(DE-2719)1012001$$kAG Breteler$$lPopulation Health Sciences$$x0
000136371 980__ $$ajournal
000136371 980__ $$aVDB
000136371 980__ $$aI:(DE-2719)1012001
000136371 980__ $$aUNRESTRICTED